CML
News
Mutation testing aids CML treatment decisions
Key clinical point:Mutation testing may aid treatment selection in patients with chronic myeloid leukemia (CML) when selecting an alternative...
News
Blood cancer drugs set to be removed from CDF
Photo courtesy of CDC England’s National Health Service (NHS) plans to remove several drugs used to treat hematologic malignancies from the...
News
Medical Roundtable: Practical Management of Chronic Myelogenous Leukemia
News
Inhibitors can target CML stem cells
Preclinical research has revealed nutrients that support the activity of chronic myelogenous leukemia (CML) stem cells and suggests these...
News
The LAST Study: CML trial examines life after TKIs
News
Combo may overcome TKI resistance in CML
Schürch, MD, PhD, (left) and Adrian Ochsenbein, MD Photo by Susi Bürki Combining a tyrosine kinase inhibitor (TKI) with a monoclonal antibody (...
News
Inhibitor could treat range of hematologic disorders
A small molecule that targets the sonic Hedgehog signaling pathway has advanced to phase 2 trials in a range of hematologic disorders. In a phase...
News
CML patients die from comorbidities, not leukemia
Key clinical point: Patients with chronic myeloid leukemia treated with imatinib are much more likely to die from comorbid conditions than from...
News
Radiation increases risk of death from CML, other leukemias
power plant in Germany Protracted exposure to ionizing radiation, even at low doses, can increase a person’s risk of dying from certain leukemias...
Conference Coverage
Nivolumab produces ‘dramatic’ responses in HL
Photo courtesy of UCLA LUGANO—The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in...
Conference Coverage
Dose reductions make ponatinib safer for CP-CML
VIENNA—Administering ponatinib at lower doses can reduce the risk of arterial occlusive events (AOE) without hindering responses in patients with...